Synlogic, Inc. SYBX
0.98 USD -0.12 (-10.55%)
Regular-session close
0.58 -0.41 -41.53%
After hours · Nov 18, 4:00 PM ET
0.9601 Day range 0.9601
0.54 52-week range 1.73
- YTD
- -12.14%
- 1 year
- -41.78%
News
defenseworld.net Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK) Synlogic (NASDAQ: SYBX - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
defenseworld.net Synlogic (NASDAQ:SYBX) Stock Price Crosses Above Fifty Day Moving Average – Here’s What Happened Shares of Synlogic, Inc. (NASDAQ: SYBX - Get Free Report) passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $0.97 and traded as high as…
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Varex Imaging Corporation (Nasdaq – VREX), Synlogic, Inc. (OTC – SYBX), Bowman Consulting Group Ltd. (Nasdaq – BWMN), Nathan's Famous, Inc. (Nasdaq – NATH) BALA CYNWYD, Pa., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
businesswire.com SYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Synlogic, Inc. (OTC: SYBX) and Caldera Therapeutics, Inc. Upon closing of the proposed…
globenewswire.com Synlogic Reports Third Quarter 2024 Financial Results WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported…
globenewswire.com Synlogic Reports Second Quarter 2024 Financial Results WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported…
investorplace.com The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits “Sell in May and go away” is a common adage in investing. It's based on the historical pattern of stocks underperforming from May to October when investors tend to stay on the sidelines.
globenewswire.com Synlogic Reports First Quarter 2024 Financial Results CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported…
zacks.com Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates Synlogic, Inc. (SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago.
globenewswire.com Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported…
globenewswire.com Synlogic Adopts Limited Duration Stockholders Rights Plan Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process Engages Ladenburg Thalmann as financial advisor to assist with previously announced…
investorplace.com Why Is Synlogic (SYBX) Stock Down 55% Today? Synlogic (NASDAQ: SYBX ) stock is falling on Friday after the clinical-stage biopharmaceutical company announced the discontinuation of its Synpheny-3 clinical trial. According to a press release…
globenewswire.com Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to…
globenewswire.com Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study
globenewswire.com Synlogic Provides Corporate Update and Outlook for 2024 - Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age -
globenewswire.com Synlogic Announces Contract with the Air Force Research Lab - Selection of Synlogic reflects Company's leadership in process development and manufacturing of therapeutics based on synthetic biology - - Selection of Synlogic reflects Company's leadership in…
globenewswire.com Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023 - Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation -
globenewswire.com Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 -
zacks.com Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com Synlogic Announces Closing of $21.0 Million Underwritten Public Offering CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform…
